XNASOFIX
Market cap649mUSD
Jan 10, Last price
17.00USD
1D
-0.76%
1Q
9.11%
Jan 2017
-53.01%
Name
Orthofix Medical Inc
Chart & Performance
Profile
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
IPO date
Apr 24, 1992
Employees
1,092
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 746,641 62.06% | 460,713 -0.81% | |||||||
Cost of revenue | 870,994 | 481,385 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (124,353) | (20,672) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 2,716 | 2,043 | |||||||
Tax Rate | |||||||||
NOPAT | (127,069) | (22,715) | |||||||
Net income | (151,395) 666.60% | (19,749) -48.54% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5,127 | 2,608 | |||||||
BB yield | -1.04% | -0.63% | |||||||
Debt | |||||||||
Debt current | 5,435 | 652 | |||||||
Long-term debt | 151,481 | 39,130 | |||||||
Deferred revenue | 11,297 | ||||||||
Other long-term liabilities | 32,598 | 18,906 | |||||||
Net debt | 123,809 | 84,390 | |||||||
Cash flow | |||||||||
Cash from operating activities | (45,753) | (11,538) | |||||||
CAPEX | (60,256) | (23,160) | |||||||
Cash from investing activities | (33,131) | (24,534) | |||||||
Cash from financing activities | 65,322 | (78) | |||||||
FCF | (340,715) | (65,575) | |||||||
Balance | |||||||||
Cash | 33,107 | 50,700 | |||||||
Long term investments | (95,308) | ||||||||
Excess cash | |||||||||
Stockholders' equity | (147,720) | 1,891 | |||||||
Invested Capital | 913,247 | 380,368 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 36,729 | 20,054 | |||||||
Price | 13.48 -34.34% | 20.53 -33.97% | |||||||
Market cap | 495,110 20.26% | 411,699 -32.75% | |||||||
EV | 618,919 | 496,089 | |||||||
EBITDA | (63,755) | 11,403 | |||||||
EV/EBITDA | 43.51 | ||||||||
Interest | 8,631 | 1,288 | |||||||
Interest/NOPBT |